Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Clinical Trials

Background:

• Management of patent ductus arteriosus (PDA) in preterm infants remains a significant clinical challenge.
• Existing treatment strategies for PDA carry potential risks and benefits that require careful consideration.

Purpose of the Study:

• To compare expectant management versus active treatment for protocol-defined PDA in preterm infants.
• To assess the impact of these management strategies on the incidence of death or bronchopulmonary dysplasia (BPD).

Main Methods:

• A randomized clinical trial involving 482 infants born between 22-28 weeks' gestation with a diagnosed PDA.
• Infants were randomized to either expectant management or active pharmacological treatment (acetaminophen, ibuprofen, or indomethacin).
• Primary outcome was death or BPD at 36 weeks' postmenstrual age.

Main Results:

• No significant difference in the combined outcome of death or BPD between expectant management (80.9%) and active treatment (79.6%).
• Expectant management group demonstrated significantly higher survival rates (95.9%) compared to the active treatment group (90.4%).
• Lower incidence of death due to infections was observed in the expectant management group.

Conclusions:

• Expectant management of PDA in extremely preterm infants is not associated with an increased risk of death or BPD.
• Expectant management appears to improve survival rates in this vulnerable population.
• These findings suggest a potential shift in the management paradigm for PDA in preterm neonates.